However, among other targeted therapies, tyrosine kinase inhibitors such as erlotinib or gefitinib are currently being used to treat NSCLC patients who have mutated or overactivated EGFR signaling in tumor cells, which play an important role in sustained cell proliferation [22,24,25,26]. Here, EGFR is linked to neoplasm.